Skip to main content
SpringerLink
Log in
Book cover

Complement and Kidney Disease pp 149–163Cite as

Therapeutic strategies for atypical and recurrent hemolytic uremic syndromes (HUS)

  • Chapter

Part of the book series: Progress in Inflammation Research ((PIR))

Conclusions

Therapy of recurrent/aHUS is not evidence based. However, several reports in the literature and the personal experience of the authors suggests that many patients with complement disorders respond well to any form of plasma therapy. Most centers prefer plasma exchange in the beginning and continue with plasma infusion as mainstay or prophylaxis. Despite this active and vigorous regimen many patients succumb to end-stage renal disease. Transplantation of either kidney alone or combined kidney/liver transplantation bear a high risk of recurrence. New therapeutic strategies are therefore absolutely mandatory. Hopefully, new insights in the mechanisms of disease and perhaps new complement inhibitors (such as humanized anti C5 antibodies) may improve treatment and outcome of these poor patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zimmerhackl LB (1998) Epidemiology, pathogenesis and therapeutic modalities in hemolytic-uremic syndrome. Kidney Blood Press Res 21: 290–292

    Article  CAS  PubMed  Google Scholar 

  2. Gasser C, Gautier E, Steck A, Siebenmann Re, Oechslin R (1955) Hemolytic-uremic syndromes: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 85: 905–909

    CAS  PubMed  Google Scholar 

  3. Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB (2002) Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 186: 493–500

    Article  PubMed  Google Scholar 

  4. Zimmerhackl LB (2000) E. coli, antibiotics, and the hemolytic-uremic syndrome. N Engl J Med 342: 1990–1991

    Article  CAS  PubMed  Google Scholar 

  5. Sutor AH, Thomas KB, Prufer FH, Grohmann A, Brandis M, Zimmerhackl LB (2001) Function of von Willebrand factor in children with diarrhea-associated hemolytic-uremic syndrome (D+ HUS). Semin Thromb Hemost 27: 287–292

    CAS  PubMed  Google Scholar 

  6. Sautter S (2004) Klinischer Verlauf und Veränderungen im Komplementsystem bei Kindern mit rekurrierendem Hämolytisch-urämischem Syndrom. Doctoral thesis. Medical University Innsbruck

    Google Scholar 

  7. Ruggenenti P, Remuzzi G (1998) Pathophysiology and management of thrombotic microangiopathies. J Nephrol 11: 300–310

    CAS  PubMed  Google Scholar 

  8. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L (2004) Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15: 787–795

    Article  CAS  PubMed  Google Scholar 

  9. Appel G, Cook TH, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris J, Lanning L, Lutz HU, Meri S et al. (2005) Disease of the month: Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 16: 1392–1403

    Article  PubMed  Google Scholar 

  10. Ross SC, Densen P (1984) Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Balt) 63: 243–273

    CAS  Google Scholar 

  11. Würzner R, Orren A, Potter P, Morgan BP, Ponard D, Spath P, Brai M, Schulze M, Happe L, Götze O (1991) Functionally active complement proteins C6 and C7 detected in C6-and C7-deficient individuals. Clin Exp Immunol 83: 430–437

    PubMed  Google Scholar 

  12. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M (2003) Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12: 3385–3395

    Article  CAS  PubMed  Google Scholar 

  13. Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, Lopez-Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S (2005) Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 14: 703–712

    CAS  PubMed  Google Scholar 

  14. Quigg RJ (2003) Complement and the kidney. J Immunol 171: 3319–3324

    CAS  PubMed  Google Scholar 

  15. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, NIvet H, Weiss L, Fridman WH, Fremaux-Bacchi V (2005) Anti-Factor H Autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16: 555–563

    Article  CAS  PubMed  Google Scholar 

  16. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L (2004) Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 15: 787–795

    Article  CAS  PubMed  Google Scholar 

  17. (2002) Guidelines on the diagnosis and management of the thrombotic microangiopathic hemolytic anemias. Br J Haematol 120: 556–573

    Google Scholar 

  18. O’Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM (2004) British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 126: 11–28

    CAS  PubMed  Google Scholar 

  19. Rock A, Shumak KH, Buskard NA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325: 393–397

    CAS  PubMed  Google Scholar 

  20. Caletti MG, Lejarraga H, Kelmansky D, Missoni M (2004) Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome. Pediatr Nephrol 19: 1148–1152

    Article  PubMed  Google Scholar 

  21. Chiurchiu C, Ruggenenti P, Remuzzi G (2002) Thrombotic microangiopathy in renal transplantation. Annals of Transplantation 7: 28–33

    PubMed  Google Scholar 

  22. Gerber A, Kirchhoff-Moradpour AH, Obieglo S, Brandis M, Kirschfink M, Zipfel PF, Goodship JA, Zimmerhackl LB (2003) Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality. Pediatr Nephrol 18: 952–955

    Article  PubMed  Google Scholar 

  23. Landau D. Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L (2001) Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 138: 412–417

    CAS  PubMed  Google Scholar 

  24. Licht C, Weyersberg A, Heinen S, Stapenhorst L, Devenge J, Beck B, Waldherr R, Kirschfink M, Zipfel PF, Hoppe B (2005) Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 45: 415–421

    Article  CAS  PubMed  Google Scholar 

  25. Nathanson S, Fremeaux-Bacchi V, Deschenes G (2001) Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency. Pediatr Nephrol 16: 554–556

    CAS  PubMed  Google Scholar 

  26. Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann HP, Remuzzi G, Zipfel PF (2003) Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 111: 1181–1190

    Article  CAS  PubMed  Google Scholar 

  27. Ault BH, Schmidt BZ, Fowler NL, Kashtan CE, Ahmed AE, Vogt BA, Colten HR (1997) Human factor H deficiency Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 272: 25168–25175

    Article  CAS  PubMed  Google Scholar 

  28. Loirat C, Niaudet P (2003) The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 18: 1095–11101

    Article  PubMed  Google Scholar 

  29. Filler G, Radhakrishan S, Strain L, Hill Andrew, Knoll G, Goodship TH (2004) Challenges in the management of infantile factor H associated hemolytic uremic syndrome. Pediatr Nephrol 19: 908–911

    PubMed  Google Scholar 

  30. Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LAH, Wetzels JFM (2003) Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejection. Transplantation 76: 821–826

    PubMed  Google Scholar 

  31. Pirson Y, Lefebvre C, Lambert C, Warwicker P, Goodship T (2004) Familial hemolytic uremic syndrome: a privileged observation. Bull Mem Acad R Med Belg 159: 191–194

    CAS  PubMed  Google Scholar 

  32. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y et al (2003) Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 100: 12966–12971

    CAS  PubMed  Google Scholar 

  33. Mollnes TE (2004) Therapeutic manipulation in the complement system. In: J Szebeni (ed): The Complement System. Novel roles in health and disease. Kluwer, Norwell, Dordrecht, 483–516

    Google Scholar 

  34. Morgan BP, Harris CL (2003) Complement therapeutics; history and current progress. Mol Immunol 40: 159–170

    Article  CAS  PubMed  Google Scholar 

  35. Thurman JM, Lucia MS, Ljubanovic D, Holers VM (2005) Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 67: 524–530

    Article  CAS  PubMed  Google Scholar 

  36. Zimmerman JL, Dellinger RP, Straube RC, Levin JL (2000) Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 28: 3149–3154

    CAS  PubMed  Google Scholar 

  37. Würzner R, Schulze M, Happe L, Franzke A, Bieber FA, Oppermann M, Götze O (1991) Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies. Complement Inflamm 8: 328–340

    PubMed  Google Scholar 

  38. Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA (1995) Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96: 1564–1572

    CAS  PubMed  Google Scholar 

  39. Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD, Dewar M, Elefteriades J, Hines R, Kopf G et al (1999) Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100: 2499–2506

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pediatrics and Hygiene, Microbiology and Social Medicine, Innsbruck Medical University, Anichstr. 35, A-6020, Innsbruck, Austria

    Reinhard Würzner & Lothar B. Zimmerhackl

Authors
  1. Reinhard Würzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lothar B. Zimmerhackl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knoell Institute, Beutenbergstr. 11a, D-07745, Jena, Germany

    Peter F. Zipfel

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Würzner, R., Zimmerhackl, L.B. (2006). Therapeutic strategies for atypical and recurrent hemolytic uremic syndromes (HUS). In: Zipfel, P.F. (eds) Complement and Kidney Disease. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7428-4_9

Download citation

Publish with us

Policies and ethics

Search

Navigation